Daily GLP-1 tablets are widening the race to dominate the obesity drug market.
Analysts expect the sector to reach about $200bn by the early 2030s.
The new pills offer a simpler alternative to weekly injections and attract new patients.
Novo Nordisk has launched the first oral Wegovy in the US with strong early demand.
Users say pills provide steady appetite control and remove the need for needles or refrigeration.
Lower prices also make them more accessible for people without full insurance cover.
Rival Eli Lilly is preparing its own tablet, orforglipron, which does not require fasting.
Competition is intensifying as more companies develop oral and combination treatments.
Injections still lead to greater weight loss and will likely remain important for severe obesity.
Pills are expected to expand the market by appealing to overweight patients and new users.
Rising global obesity rates, broader insurance coverage and falling costs are driving demand.
Researchers say most eligible patients still receive no treatment, leaving major growth ahead.
